Article information
Abstract
An increasing number of patients who are receiving anticoagulation or antiplatelet therapy require cutaneous surgery. Such pharmacotherapies are usually suspended based on experience in gynecologic, thoracic, and abdominal surgery. However, this practice may increase the risk of suffering a thromboembolic event. We review perioperative management of anticoagulant and antiplatelet therapy, complications associated with suspending therapy, and side effects.
Key words:
anticoagulants
warfarin
heparin
surgery
acetylsalicylic acid
bleeding
Resumen
Cada vez es mayor el número de pacientes que recibe tratamiento anticoagulante o antiagregante y que debe someterse a cirugía cutánea. Interrumpir estos tratamientos para prevenir el sangrado es una práctica habitual, extrapolada de las experiencias en cirugía ginecológica, torácica y abdominal. En este contexto, la suspensión de dichos tratamientos puede incrementar el riesgo de sufrir un evento tromboembólico. Realizamos una revisión sobre el manejo peroperatorio de los tratamientos anticoagulantes y antiagregantes, de las complicaciones acontecidas tras su suspensión, así como de sus efectos secundarios.
Palabras clave:
anticoagulantes
warfarina
heparina
cirugía
ácido acetilsalicílico
sangrado
Full text is only aviable in PDF
References
[1.]
M. Khalifeh, R. Redett.
The management of patients on anticoagulants prior to cutaneous surgery: case report of a thromboembolic complication, review of the literature, and evidence-based recommendations.
Plast Reconstr Surg, 118 (2006), pp. 110-117
[2.]
C.F. Schanbacher, R.G. Bennet.
Postoperative stroke after stopping warfarin for cutaneous surgery.
Dermatol Surg, 26 (2000), pp. 785-789
[3.]
O. Kovich, C.C. Otley.
Perioperative management of anticoagulants and platelet inhibitors for cutaneous surgery: a survey of current practice.
Dermatol Surg, 28 (2002), pp. 513-517
[4.]
J. Alcalay, R. Alkalay.
Controversies in perioperative management of blood thinners in dermatologic surgery: continue or discontinue?.
Dermatol Surg, 30 (2004), pp. 1091-1094
[5.]
J. Hirsh, J.E. Dalen, D.R. Anderson, L. Poller, H. Bussey, J. Ansell, et al.
Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range.
Chest, 119 (2001), pp. 8S-21S
[6.]
C. Kearon, J. Hirsh.
Management of anticoagulation before and after elective surgery.
N Engl J Med, 22 (1997), pp. 506-511
[7.]
J. Alcalay.
Cutaneous surgery in patients receiving warfarin therapy.
Dermatol Surg, 27 (2001), pp. 756-758
[8.]
C.C. Otley, J.L. Fewkes, W. Frank, S.M. Olbricht.
Complications of cutaneous surgery in patients who are taking warfarin, aspirin, or nonsteroidal anti-inflammatory drugs.
Arch Dermatol, 132 (1996), pp. 161-166
[9.]
E. Kargi, O. Babuccu, M. Hosnuter, B. Babuccu, C. Altinyazar.
Complications of minor cutaneous surgery in patients under anticoagulant treatment.
Aesth Plast Surg, 26 (2002), pp. 483-485
[10.]
E.M. Billingsley, M.E. Maloney.
Intraoperative and postoperative bleeding problems in patients taking warfarin, aspirin, and nonsteroidal anti-inflammatory agents: a prospective study.
Dermatol Surg, 23 (1997), pp. 381-385
[11.]
A. Ah-Weng, S. Natarajan, S. Velangi, J.A.A. Langtry.
Perioperative monitoring of warfarin in cutaneous surgery.
Br J Dermatol, 149 (2003), pp. 386-389
[12.]
A.J. Dixon, M.P. Dixon, J.B. Dixon.
Bleeding complications in skin cancer surgery are associated with warfarin but not aspirin therapy.
Br J Surg, 94 (2007), pp. 1356-1360
[13.]
C. Blasdale, C.M. Lawrence.
Postoperative bleeding and warfarin.
Br J Dermatol, 158 (2008), pp. 522-526
[14.]
J.A. Heit.
Perioperative management of the chronically anti-coagulated patient.
J Thromb Thrombolysis, 77 (2001), pp. 81-87
[15.]
E.H. Kincaid, M.L. Monroe, D.L. Saliba, N.D. Kon, W.G. Byerly, M.G. Reichert.
Effects of perioperative enoxaparin versus unfractionated heparin on bleeding indices in patients undergoing coronary artery bypass grafting.
Ann Thorac Surg, 76 (2003), pp. 124-128
[16.]
B. Medalion, G. Frenkel, P. Patachenko, E. Hauptman, L. Sasson, A. Schachner.
Preoperative use of enoxaparin is not a risk factor for postoperative bleeding after coronary artery bypass surgery.
J Thorac Cardiovasc Surg, 126 (2003), pp. 1875-1879
[17.]
G. Stables, C.M. Lawrence.
Management of patients taking anticoagulant, aspirin, non-steroidal anti-inflammatory and other anti-platelet drugs undergoing dermatological surgery.
Clin Exp Dermatol, 27 (2002), pp. 432-435
[18.]
A. Buvanendran, J.S. Kroin, K.J. Tuman, T.R. Lubenow, D. Elmofty, M. Moric, et al.
Effects of perioperative administration of a selective cyclooxygenase 2 inhibitor on pain management and recovery of function after knee replacement: a randomized controlled trial.
JAMA, 290 (2003), pp. 2411-2418
[19.]
G.R. Bartlett.
Does aspirin affect the outcome of minor cutaneous surgery?.
Br J Plast Surg, 54 (2001), pp. 214-216
[20.]
C. Lawrence, A. Sakuntabhai, S. Tiling-Grosse.
Effect of aspirin and nonsteroidal anti-inflammatory drug therapy on bleeding complications in dermatological surgery patients.
J Am Acad Dermatol, 31 (1994), pp. 988-992
[21.]
M.J. Quinn, D.J. Fitzgerald.
Ticlopidine and clopidogrel.
Circulation, 100 (1999), pp. 1667-1672
[22.]
L. Valeyrie-Allanore, B. Sassolas, J.C. Roujeau.
Drug-induced skin, nail and hair disorders.
Drug Saf, 30 (2007), pp. 1011-1030
[23.]
J.Z. Litt.
Drug eruption reference manual.
10th ed., Taylor and Francis, (2004),
[24.]
A.J. Birchner, T. Harr, L. Hohenstein, D.A. Tsakiris.
Hypersensitivity reactions to anticoagulant drugs: diagnosis and management options.
Allergy, 61 (2006), pp. 1432-1440
[25.]
M. Valdivielso, I. Longo, M. Lecona, P. Lázaro.
Cutaneous necrosis induced by acenocumarol.
J Eur Acad Dermatol Venereol, 18 (2004), pp. 211-215
[26.]
D.W. Essex, S.S. Wynn, D.K. Jin.
Late-onset warfarin-induced skin necrosis: case report and review of the literature.
Am J Hematol, 57 (1998), pp. 233-237
[27.]
D.B. Talmadge, A.C. Spyropoulos.
Purple toes syndrome associated with warfarin therapy in a patient with antiphospholipid syndrome.
Pharmacotherapy, 23 (2003), pp. 674-677
[28.]
A.P. Soisson, K.K. Vu, P.C. Brittain, I. Chamales.
An unusual cutaneous reaction to anticoagulant therapy.
Mil Med, 159 (1994), pp. 252-253
[29.]
M.H. Kruis-de Vries, B.H. Stricker, P.J. Coenraads, J.P. Nater.
Maculopapular rash due to coumarin derivatives.
Dermatologica, 178 (1989), pp. 109-111
[30.]
S.J. Anthony, S.K. Krick, P.M. Mehta.
Unusual cutaneous adverse reaction to warfarin therapy.
South Med J, 86 (1993), pp. 1413-1414
[31.]
P. Komericki, R. Grims, B. Kränke, W. Aberer.
Acute generalized exanthematous pustulosis from dalteparin.
J Am Acad Dermatol, 57 (2007), pp. 718-721
[32.]
L. Mureebe, D. Silver.
Heparin-induced thrombocytopenia: pathophysiology and management.
Vasc Endovascular Surg, 36 (2002), pp. 163-170
[33.]
A. Toll, F. Gallardo, E. Abella, J. Fontcuberta, C. Barranco, R.M. Pujol.
Low-molecular-weight heparin-induced skin necrosis: a potential association with pre-existent hypercoagulable states.
Int J Dermatol, 44 (2005), pp. 964-966
[34.]
T.E. Warkentin.
Heparin-induced thrombocytopenia: a ten-year retrospective.
Annu Rev Med, 50 (1999), pp. 129-147
[35.]
U. Jappe, H. Gollnick.
Allergy to heparin, heparinoids, and recombinant hirudin. Diagnostic and therapeutic alternatives.
Hautartzt, 50 (1999), pp. 406
[36.]
CAPRIE Steering Comittee.
A randomized, blinded trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE).
Lancet, 348 (1996), pp. 1329-1339
[37.]
A. Zakarija, N. Bandarenko, D.K. Pandey, A. Auerbach, D.W. Raisch, B. Kim, et al.
Clopidogrel-associated TTP: an update of pharmacovigilance efforts conducted by independent researchers, pharmaceutical suppliers, and the Food and Drug Administration.
Stroke, 35 (2004), pp. 533-537
[38.]
M. Meissner, C. Beier, M. Wolter, R. Kaufmann, J. Gille.
Suberythrodermic pustular psoriasis induced by clopidogrel.
Br J Dermatol, 155 (2006), pp. 627-644
[39.]
S. Dogra, A.J. Kanwar.
Clopidogrel bisulphate-induced photosensitive lichenoid eruption: first report.
Br J Dermatol, 148 (2003), pp. 609-610
[40.]
A. Comert, S. Akgun, A. Civelek, M. Kavala, S. Sarigül, T. Yildirim, et al.
Clopidogrel-induced hypersensitivity syndrome associated with febrile pancytopenia.
Int J Dermatol, 44 (2005), pp. 882-884
[41.]
M.P. Doogue, E.J. Begg, P. Bridgman.
Clopidogrel hypersensitivity syndrome with rash, fever, and neutropenia.
Mayo Clinic Proc, 80 (2005), pp. 1368-1370
[42.]
E. Pintor, M. Sanmartín, L. Azcona, R. Hernández, A. Fernández-Cruz, C. Macaya.
Vasculitis leucocitoclástica en relación con ticlopidina.
Rev Esp Cardiol, 54 (2001), pp. 114-116
[43.]
T.R. Whetsel, D.M. Bell.
Rash in patients receiving ticlopidine after coronary stent placement.
Pharmacotherapy, 19 (1999), pp. 228-231
[44.]
K. Fukushima, Y. Kobayashi, T. Okuno, Y. Nakamura, M. Sakakibara, T. Nakayama, et al.
Incidence of side-effects of ticlopidine after sirolimus-eluting stent implantation.
Circ J, (2007), pp. 617-619
[45.]
C.M. García, R. Carmena, R. García, P. Berges, E. Camacho, M.P. Cotter, et al.
Fixed drug eruption from ticlopidine, with positive lesional patch test.
Contact Dermatitis, 44 (2001), pp. 40-41
[46.]
D.H. His, D.J. Mock, T.A. Rocco.
Toxic erythroderma due to ticlopidine.
N Engl J Med, 340 (1999), pp. 1212
[47.]
G. Yosipovitz, E. Rechavia, M. Feinmesser, M. David.
Adverse cutaneous reactions to ticlopidine in patients with coronary stents.
J Am Acad Dermatol, 41 (1999), pp. 473-476
[48.]
I. Kurokawa, M. Umehara, S. Nishijima.
Lichen planus-type drug eruption resulting from ticlopidine.
Int J Dermatol, 44 (2005), pp. 437-438
[49.]
F. Fabris, G. Luzzatto, M.T. Sartori, I. Zanella.
A paradoxical side-effect of antiaggregating treatment with ticlopidine: the Moschowitz syndrome.
Haematologica, 84 (1999), pp. 760-762
[50.]
C.L. Bennet, P.D. Weinberg, K. Rozenberg-Ben-Dor, R.D. Yarnold, H.C. Kwaan, D. Green.
Thrombotic thrombocytopenic purpura associated with ticlopidine: a review of 60 cases.
Ann Intern Med, 128 (1998), pp. 541-544
[51.]
J. Thachil, A. Gatt, V. Martlew.
Management of surgical patients receiving anticoagulation and antiplatelet agents.
Br J Surg, 95 (2008), pp. 1437-1448
Copyright © 2009. Academia Española de Dermatología y Venereología and Elsevier España, S.L.
